nct_id: NCT05067283
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2021-10-05'
study_start_date: '2021-12-17'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: carboplatin'
  - drug_name: 'Drug: leucovorin'
  - drug_name: 'Drug: MK-1084'
  - drug_name: 'Biological: cetuximab'
  - drug_name: 'Drug: pemetrexed'
  - drug_name: 'Drug: 5-fluorouracil'
  - drug_name: 'Biological: Pembrolizumab'
  - drug_name: 'Drug: oxaliplatin'
long_title: A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability,
  PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies
  in Participants With KRAS G12C Mutant Advanced Solid Tumors
last_updated: '2025-11-21'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE1
principal_investigator: NA
principal_investigator_institution: Merck Sharp & Dohme LLC
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 830
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- 'For all participants:'
- '* Has measurable disease by RECIST 1.1 criteria'
- '* Has adequate organ function'
- '* Male participants agree to protocol-specified contraception requirements including
  refraining from donating sperm and using protocol-specified contraceptives unless
  confirmed to be azoospermic'
- '* Female participants must not be pregnant or breastfeeding, and must agree to
  protocol-specified contraceptive requirements and must have a negative highly sensitive
  pregnancy test within 24 hours (for a urine test) or 72 hours (for a serum test)
  before the first dose of study intervention'
- For Arm 1 - Has locally advanced unresectable or metastatic solid-tumor malignancy
  with histologically OR blood-based confirmation of KRAS G12C mutation who has received
  at least 1 line of therapy for systemic disease
- For Arm 2
- "\\- Has an untreated metastatic non-small cell lung cancer (NSCLC) with histologically\
  \ OR blood-based confirmation of KRAS G12C mutation and histologic confirmation\
  \ of programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) \u2265\
  1%"
- For Arm 3
- '* Has locally advanced unresectable or metastatic solid-tumor malignancy with histologically
  or blood-based confirmation of KRAS G12C mutation who has received at least 1 line
  of therapy for systemic disease Expansion Group A: 2L+NSCLC'
- '* Has histologically or cytologically confirmed diagnosis of unresectable or metastatic
  NSCLC with histological or blood-based confirmation of KRAS G12C mutation and submits
  archival tumor sample'
- '* Previous treatment failure of at least 1 line of systemic therapy Expansion Group
  B'
- '* Has locally advanced unresectable or metastatic solid-tumor malignancy, excluding
  NSCLC or CRC, with histologically or blood- based confirmation of KRAS G12C mutation
  who has received at least 1 line of therapy for systemic disease'
- Arm 4 only - Has an untreated advanced or metastatic nonsquamous NSCLC with histologically
  or blood-based confirmation of KRAS G12C mutation
- Arm 5 only
- '* Histologically or cytologically confirmed diagnosis of locally advanced unresectable
  or metastatic colorectal adenocarcinoma and with histologically or blood-based confirmation
  of KRAS G12C mutation'
- '* Previous treatment failure of one or 2 previous line(s) of systemic therapy'
- Arm 6 only
- \- Locally advanced unresectable or metastatic colorectal adenocarcinoma with histologically
  or blood-based confirmation of KRAS G12C mutation
- 'Exclude - Exclusion Criteria:'
- Exclude - * Has received chemotherapy, definitive radiation, or biological cancer
  therapy within 4 weeks (2 weeks for palliative radiation) before first dose of study
  intervention
- Exclude - * Has a history of second malignancy, unless potentially curative treatment
  has been completed with no evidence of malignancy for 5 years
- Exclude - * Has clinically active central nervous system (CNS) metastases and/or
  carcinomatous meningitis
- Exclude - * Has an active infection requiring systemic therapy
- Exclude - * Known history of HIV infection or. has a known history of Hepatitis
  B virus or known active Hepatitis C virus infection
- Exclude - * Has a history of interstitial lung disease, noninfectious pneumonitis
  requiring active steroid therapy, or ongoing pneumonitis
- Exclude - * Has an active autoimmune disease requiring systemic therapy
- Exclude - * Has not fully recovered from any effects of major surgical procedure
  without significant detectable infection
- 'Exclude - * Has one or more of the following ophthalmological findings/conditions:
  intraocular pressure \>21 mm Hg and/or any diagnosis of glaucoma; diagnosis of central
  serous retinopathy, retinal vein occlusion, or retinal artery occlusion and/or a
  diagnosis of retinal degenerative disease'
- Exclude - * Has received live or live-attenuated vaccine within 4 weeks of study
  start
- Exclude - Arm 4 Only
- "Exclude - * Is unable to interrupt aspirin or other nonsteroidal anti-inflammatories\
  \ (NSAIDs), other than an aspirin dose \u22641.3 grams per day, for at least 2 days\
  \ (5 days for long-acting agents \\[for example, piroxicam\\]) before, during, and\
  \ for at least 2 days after administration of pemetrexed."
- Exclude - * Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone
short_title: A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Merck Sharp & Dohme LLC
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: This is a study evaluating the safety, pharmacokinetics, and efficacy of
  MK-1084 alone, and MK-1084 plus other combination therapies in participants with
  advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog
  G12C (KRAS G12C) mutation.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Arm 1
      arm_internal_id: 0
      arm_description: Participants will receive daily oral escalating doses of up
        to 800 mg of MK-1084 until progressive disease or discontinuation. Dosing
        regimen may be adjusted based on safety.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: MK-1084'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Arm 2
      arm_internal_id: 1
      arm_description: Participants will receive MK-1084 daily oral escalating dose
        of up to 800 mg plus pembrolizumab given as a 200 mg intravenous infusion
        once every 21-day cycle up to a total of 35 cycles (up to \~24 months). Treatment
        with MK-1084 will continue until progressive disease or discontinuation. Dosing
        regimen may be adjusted based on safety.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: MK-1084'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Biological: Pembrolizumab'
        level_internal_id: 1
        level_suspended: N
    - arm_code: Arm 3
      arm_internal_id: 2
      arm_description: Participants will receive alternate formulation of MK-1084
        until progressive disease or discontinuation. Dosing regimen may be adjusted
        based on safety.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: MK-1084'
        level_internal_id: 0
        level_suspended: N
    - arm_code: Arm 4
      arm_internal_id: 3
      arm_description: Participants will receive MK-1084 daily oral dose plus an intravenous
        infusion of pembrolizumab (200 mg) once every 21-day cycle for up to 35 cycles
        (up to \~24 months). Participants will also receive carboplatin (per label)
        and pemetrexed (per label) once every 21-day cycle for the first 4 cycles.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: MK-1084'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Biological: Pembrolizumab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: carboplatin'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: pemetrexed'
        level_internal_id: 3
        level_suspended: N
    - arm_code: Arm 5
      arm_internal_id: 4
      arm_description: Participants will receive MK-1084 daily oral dose plus an intravenous
        infusion of cetuximab (per label) every 2 weeks of each 28-day cycle.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: MK-1084'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Biological: cetuximab'
        level_internal_id: 1
        level_suspended: N
    - arm_code: Arm 6
      arm_internal_id: 5
      arm_description: Participants will receive MK-1084 daily oral dose. Additionally,
        participants receive an intravenous infusion of cetuximab (per label) every
        2 weeks of each 28-day cycle, oxaliplatin (per label) for first 6 cycles,
        and leucovorin (per label) and 5-fluorouracil (per label) once every 14-days.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: MK-1084'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Biological: cetuximab'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: oxaliplatin'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: leucovorin'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: 5-fluorouracil'
        level_internal_id: 4
        level_suspended: N
    match:
    - and:
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Locally Advanced
          - Metastatic
          - Unresectable
          - Untreated
          oncotree_primary_diagnosis: _SOLID_
      - or:
        - genomic:
            hugo_symbol: KRAS
            variant_category: Mutation
